Company Description
Breathe BioMedical is a medical technology company focused on developing a breath test to be used as an adjunctive test to mammography screening to detect early-stage breast cancer in women with dense breast tissue.
Breathe BioMedical is in the development stage of our Breast Cancer Breath Test. Over the next two years we have verification and validation studies planned for the components and the Breast Cancer Breath Test, as well as a large multi-center clinical study planned to evaluate the safety and efficacy of the Breast Cancer Breath Test, subject to discussions with regulatory authorities, and build our machine learning model for breast cancer.
We are currently conducting a proof-of-concept study. Data collection will be completed in 3Q2024.
| Country | Canada |
| Founded | 2005 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 26 |
| CEO | William Dawes |
Contact Details
Address: 191 Halifax Street Moncton, NB E1C 9R6 Canada | |
| Phone | (506) 855-2400 |
| Website | breathebiomedical.com |
Stock Details
| Ticker Symbol | BRTH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| CIK Code | 0002004349 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| William Dawes | Chief Executive Officer |
| Sandra Veenstra | Chief Regulatory Officer |
| Peili Miao | Chief Financial Officer |
| Christopher Purves | Chief Technology Officer |
| Dr. Rachel Brem | Chief Medical Officer and Director |
| Joanne Young | Vice President, Clinical |
| Jean Nadeau | Chairman of the Board |
| Telfer Hanson | Vice Chairman of the Board |
| Dr. Norman Betts | Director |
| Romeo Goguen | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 7, 2024 | F-1 | Registration statement for certain foreign private issuers |
| May 20, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Apr 11, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Mar 4, 2024 | DRS | [Cover] Draft Registration Statement |